**Core Concept**
Buprenorphine is a partial agonist at the mu-opioid receptor, which is a key target for opioid analgesia and addiction. This partial agonism is responsible for its unique pharmacological profile, including both analgesic and opioid-receptor mediated effects.

**Why the Correct Answer is Right**
Buprenorphine binds to the mu-opioid receptor with high affinity, but its efficacy is limited compared to full agonists like morphine. This partial agonism is thought to occur due to the allosteric modulation of the receptor by buprenorphine, which reduces the receptor's ability to undergo full activation. As a result, buprenorphine produces a ceiling effect on respiratory depression, making it a safer option for opioid substitution therapy.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because buprenorphine is not a full agonist at the delta-opioid receptor, nor does it have significant activity at this site.
**Option B:** This option is incorrect because buprenorphine is not a partial agonist at the kappa-opioid receptor; instead, it acts as an antagonist at this site.
**Option C:** This option is incorrect because buprenorphine does not have significant activity at the NMDA receptor, which is a target for other opioids like ketamine.

**Clinical Pearl / High-Yield Fact**
Buprenorphine's partial agonism at the mu-opioid receptor makes it a valuable tool for managing opioid addiction and pain, as it reduces the risk of respiratory depression and overdose while still providing analgesia.

**Correct Answer: C.**